Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company''s lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
最新股票文章

為何麥可·貝瑞(Michael Burry)剛剛清倉所有股票
麥可·貝瑞剛剛拋售了超過7,000萬美元的股票,清空了他的整個投資組合,只保留一支股票,並對這家公司加碼,而其他投資人則紛紛出逃。
18:37, 22 7月 2025